Myristic acid: effects on HDL, omega3, LDL oxidation and membrane fluidity;L'acide myristique du lait: effets sur le HDL-cholestérol, les acides gras ω3, les LDL oxydées et la fluidité membranaire

Sciences des Aliments

Volumn 28, Issue 1-2, 2008, Pages 134-142

  Dabadie, H ^a   Peuctiant, E ^b   Motta, C ^c   Bernard, M ^a   Mendy, F ^d  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c Inst de Rech Contre le Cancer IRCC   (France)

^d CNIEL   (France)

Author keywords

Hdl cholesterol; Lp(a); Membrane fluidity; Milk; Myristic acid; N 3 fatty acids; Oxidized LDL

Indexed keywords

BRASSICA NAPUS;

EID: 63849138826     PISSN: 02408813     EISSN: None     Source Type: Journal    
DOI: 10.3166/sda.28.134-142     Document Type: Article

References (29)

1. Health Revolutionary: the life and work of Ancel Keys (Documenting Public Health Leadership Project of the Associations of Schools of Public Health and the Health Resources and Services Administration). 2002. DVD Minneapolis, MN: University of Minnesota School of Public Health.
2. KEYS A., 1980. Seven countries: a multiva-riate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press.
3. ORDOVAS J.M., 2005. Diet-heart hypothesis: will diversity bring reconciliation? Am. J. Clin. Nutr., 82, 919-20.
4. STEINBERG D., PARTHASARATHY S., CAREW T.E., KHOO J.C., WITZTUM J.L. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its athe-rogenicity. N. Engl. J. Med., 320, 915-24.
5. TSIMIKAS S., 2006. Measures of oxidative stress. Clin. Lab. Med., 26, 571-90.
6. BABIOR B.M., 1984. Oxidants from phagocytes: agents of defense and destruction. Blood, 64, 959-66.
7. BABIOR B.M., 2000. Phagocytes and oxidative stress. Am. J. Med., 109, 33-44.
8. HU F.B., STAMPFER M.J., MANSON J.E., ASCHERIO A., COLDITZ G.A., SPEIZER F.E., HENNEKENS C.H., WILLETT W.C., 1999. Dietary saturated fats and their food sources in relation to the risk of coronary heart disease in women. Am. J. Clin. Nutr., 70, 1001-08.
9. DABADIE H., PEUCHANT E., BERNARD M., LERUYET P., MENDY F., 2005. Moderate intake of myristic acid in sn-2 position has beneficial lipidic effects and enhances DHA of cholesteryl esters in an interventional study. J. Nutr. Biochem., 16, 375-82.
10. DABADIE H., MOTTA C, PEUCHANT E., LERUYET P., MENDY F., 2006. Variations in daily intakes of myristic and α-linolenic acids in sn-2 position modify lipid profile and red blood cell membrane fluidity. Br. J. Nutr., 96, 283-9.
11. TSIMIKAS S., LAU H.K., HAN K.R., 2004. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation, 109, 3164-70.
12. MOZZAFARIAN D., RIMM E.B., HERRING-TON D.M., 2004. Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women. Am. J. Clin. Nutr., 80, 1175-84.
13. THOLSTRUP T., VESSBY B., SANDSTROM B., 2003. Difference in effect of myristic and stearic acid on plasma HDL cholesterol within 24h in young men. Eur. J. Clin. Nutr., 57, 735-42.
14. LOISON C, MENDY F., SEROUGNE C, LUTTON C, 2002. Dietary myristic acid modifies the HDL-cholesterol concentration and liver scavenger receptor B1 expression in the hamster. Br J. Nutr., 87, 1-13.
15. JONAS A., 1991. Lecithin cholesterol acyl-transferase in the metabolism of high-density lipoproteins. Biochem Biophys Acta, 1084, 205-20.
16. VAYSSE-BOUE C, DABADIE H., PEU-CHANT E., LERUYET P., MENDY F., GIN H., COMBE N., 2007. Moderate dietary intake of myristic and α-linolenic increases lecithin-cholesterol acyltransferase activity. Lipids, 42, 717-22.
17. BABIN F., RODRIGUEZ A., SARDA P., VAN-DEPUTTE B., MENDY F., DESCOMPS, 2000. Alpha linolenic acid in cholesterol esters: a marker of alphalinolenic acid intake in new-boms. Eur J. Clin. Nutr., 54, 840-3.
18. GOYENS P.L.L., ZOCK P.L., KATAN M.B., MENSINK R.P., 2006. Nearly all ALA from the plasma phospholipids was converted into EPA in humans. Am J. Clin. Nutr., 84, 44-53.
19. JAN S., GUILLOU H., D'ANDREA S., DAVAL S., BOURIEL M., RIOUX V., LEGRAND P., 2004. Myristic acid increases Δ6-desaturase activity in cultured rat hepatocytes. Reprod Nutr. Dev., 44, 131-40.
20. 5 reductase requires myristic acid for association with outer mitochondrial but not ER membranes. J. Cell Biol., 135, 1501-13.
21. TSIMIKAS S., KIECHL S., WILLEIT J., MAYR M., MILLER E.R., KRONENBERG F., XU Q., BERGMARK C., WEGER S., OBERHOLLEN- ZER F., WITZTUM J.L., 2006. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis. J. Am. Coll. Cardiol., 47, 2219-28.
22. TSIMIKAS S., BRILAKIS E.S., MILLER E.R., MCCONNELL J.P., LENNON R.J., KORN-MAN K.S., WIZTUM J.L., BERGER P.B., 2005. Oxidized phospholipids, Lp(a)lipopro-tein, and coronary artery disease. N. Engl. J. Med., 353, 46-57.
23. KOSCHINSKY M.L., MARCOVINA S.M., 2004. Structure-function relationships in apo-lopoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr. Opin. Lipi-dol., 15, 167-74.
24. 2 and lipoxygenase. J. Lipid. Res., 47, 1054-62.
25. 3α-VI in human urine. J. Lipid. Res., 47, 2515-24.
26. PEELMAN F., VANDEKERCKHOVE J., ROS-SENEU M., 2000. Structure and function of LCAT. New insights from structural prediction in animal models. Curr. Opin. Lipidol., 11, 155-6.
27. FORTE T.M., SUBBANAGOUNDER G., BERLINER J.A., 2002. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J. Lipid. Res., 43, 477-85.
28. SHINITZKY M., 1982. Membrane fluidity and cellular functions. In Physiology of membrane fluidity, 1-52 (Shinitzky M, editoŕ) Boca Raton: CRC Press.
29. REES D., MILES E.A., BANERJEE T., WELLS S.J., ROYNETTE C.E., WAHLE K.W.J., CAL-DER P.C., 2006. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am. J. Clin. Nutr., 83, 331-42.